Abstract

MERAZ-BRENEZ, Andrés et al. Low dose nivolumab in metastatic mucosal melanoma: a case report. Gac. mex. oncol. [online]. 2023, vol.22, n.3, pp.140-145.  Epub Sep 29, 2023. ISSN 2565-005X.  https://doi.org/10.24875/j.gamo.23000030.

We present the case of a 77-year-old man with metastatic mucosal melanoma, unable to afford standard doses of immunotherapy, who was treated with nivolumab at a lower dose of 0.5 mg/kg every 2 weeks. Drug activity was demonstrated through both objective tumor response and an immune-related adverse event. This suggests that a lower dose of nivolumab could be a viable alternative for patients with advanced mucosal melanoma at a high risk of treatment-related financial toxicity. Further research is needed to evaluate the efficacy of lower doses of immunotherapy, including its impact on long term outcomes.

Keywords : Melanoma; Nivolumab; Geriatric oncology; Case report; Financial toxicity.